Cas:50-12-4 Mephenytoin manufacturer & supplier

Chemical Name:Mephenytoin

CAS.NO:50-12-4

Synonyms:Phenantoin;MEPHENYTOIN;mephenytoine;Methoin;Insulton;Triantoin;Mesantoin;5-ethyl-3-methyl-5-phenylhydantoin;Sedantoinal;methyl Hydantoin;EINECS 200-012-8;MFCD00270025;Methylphenetoin;Epiazin;Sedantoin

Molecular Formula:C₁₂H₁₄N₂O₂

Molecular Weight:218.25200

HS Code:2933990090

Physical and Chemical Properties:

Melting point:135-138ºC

Boiling point:N/A

Density:1.154g/cm3

Index of Refraction:

PSA:49.41000

Exact Mass:218.10600

LogP:1.74020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Phenantoin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Sedantoin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00270025 Use and application,Triantoin technical grade,usp/ep/jp grade.

Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. Mephenytoin manufacturer The company��s iPSC product platform unites stem cell biology and precision genetic engineering to create renewable master engineered iPSC lines that can be repeatedly used to mass produce cancer-fighting immune cells, replacing the high production costs, weeks of manufacturing time, and complex engineering processes required for current-generation CAR T-cell immunotherapies with an off-the-shelf product that has the potential to reach many more patients. Mephenytoin supplier The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. Mephenytoin vendor In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. Mephenytoin factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.